ScotBio's top Scientists @Joe Palmer and @Hector Mora had a great time talking about our new products; ScotBio Supablu™ and ScotBio Protein at the ‘Being Innovative about Food Innovation’ Conference at @Queen Margaret University recently. Boys In Bloom.
ScotBio ready to launch SupaBlu™ – a heat-stable natural blue colourant
ScotBio is pleased to present SupaBlu™ to market; a heat-stable natural blue food colourant, suitable as an alternative for artificial Brilliant blue FCF in various food and beverage applications.
ScotBio SupaBlu™ HS is a blue pigment specially formulated from Spirulina extract and other vegan, FDA & EFSA-approved food excipients, producing a water-soluble, vivid blue colourant with superior heat-stability versus other natural blues. This makes the product ideal for food & beverage applications which utilise a thermal process, such as pasteurisation, baking or syrup-heating in sweet-making.
ScotBio SupaBlu™ HS’s enhanced heat stability provides superior performance in ice creams, milkshakes, gummies, juices, cakes and various other applications where high temperature processing is needed. SupaBlu™ HS can also be used to create green hues by combining with yellow colourants, such as turmeric.
ScotBio produces its own Spirulina extract from microalgae grown in state-of-the-art reactor systems at the company’s new production facility in Livingston, Scotland. Using patented cultivation techniques, Spirulina is intensively and hygienically grown in a closed loop-system, allowing unparalleled quality and productivities.
For more information on ScotBio SupaBlu™ HS, or to request a sample of the product for application testing, please contact John McLaughlin, Sales Manager (J.McLaughin@scotbio.com).
ScotBio aims to battle Covid-19 and future pandemics with spirulina waste
Extracts from spirulina, the blue-green algae widely consumed as a superfood, could be turned into a therapeutic treatment for Covid-19, the common cold, and a host of other viruses, following promising initial results from research conducted by ScotBio.
ScotBio are working with the University of Edinburgh, Robert Gordon University, and the Industrial Biotechnology Innovation Centre (IBioIC) to determine how waste molecules from spirulina can be extracted and used for their natural antiviral properties. Spirulina is already used in the commercial production of a variety of products, including as a dietary supplement and for food colourants. ScotBio’s intensive ‘vertical farming of algae’ approach to producing spirulina helps to recover valuable by-products, including plant-based proteins, whilst minimising waste.By separating spirulina molecules into different chemical groups, the project has determined the most effective extracts with antiviral activity against coronaviruses, including various SARs-CoV-2 variants (the cause of Covid-19), common cold viruses, and influenza viruses.
This supports earlier studies which observed anti-HIV and anti-HSV (Herpes Simplex Virus) activity in similar compounds. These initial results show that spirulina molecules are broad-acting, have little toxicity towards mammalian cells, and could potentially form the basis of effective treatments against emerging human and animal viral diseases. Although antiviral agents are typically used for pharmaceuticals, they can also be added to products such as cosmetics – known as ‘cosmeceuticals’ – to fight against viral transmission. ScotBio are now looking at incorporating the molecule into various consumer products.
Dr Joe Palmer, product development manager, said: “Working with the project consortium has enabled us to fractionate spirulina into distinct chemical groups and then screen the extracts in a safe environment. Through that, we have identified compounds that could be particularly effective against a broad range of viruses from what was previously seen as waste. We can now work on recovering and purifying these molecules as high value ingredients.
“The next step for us is to better understand the market opportunities for these molecules and to fully resolve the relationship between molecule chemistry and their antiviral mechanisms. Our aim is for this project to be a catalyst that will unlock a large and untapped market, helping in the fight against common viruses and future pandemics.”
Liz Fletcher, director of business engagement and operations, IBioIC, commented: “ScotBio is a great example of an ambitious biotechnology company with a unique product. Previous studies on common viruses have shown that spirulina extracts can have many positive effects on the immune response to infection, and it is exciting to support ScotBio in taking this research even further. Our aim is to help companies grow by providing them with the support they need to apply their technologies to new areas.”
This preliminary research has been reported various news outlets, including The Herald and The Insider.
https://www.heraldscotland.com/business_hq/23305461.scottish-researchers-seek-cure-common-cold/
https://www.insider.co.uk/news/scottish-biotech-firm-aims-combat-29171734
W: https://www.ibioic.com/
T: https://twitter.com/IBioIC
L: https://www.linkedin.com/company/industrial-biotechnology-innovation-centre/
ScotBio expands R&D programme for coronavirus research
ScotBio is expanding its R&D programme to explore the potential of cyanobacteria to treat emerging viral pathogens, including coronaviruses. With funding from Medical Research Scotland, a new collaborative partnership with Infection Medicine at the University of Edinburgh will investigate how cyanobacterial extracts, recognized previously for their antiviral activity, can be commercially mass produced using ScotBio’s established production processes and used in the treatment of major emerging viral diseases.
ScotBio makes top prospects list for Blue Growth in Europe
ScotBio is delighted to be included in the Maritime Forum as one of the top prospects for Blue Growth in Europe. Driven by the European Maritime and Fisheries Fund, BlueInvest works to boost innovation in sustainable technologies for the blue economy by showcasing early-stage businesses, SMEs and scale-ups for investment.
Dr. Keith Bromley reflects on working with ScotBio
We wish our former Research Scientist, Dr. Keith Bromley, farewell and all the best with his new job. Read about Dr. Bromley’s journey in this brief blog post, describing how we was introduced to ScotBio, the importance of being a hub of academic collaboration, and Dr. Bromley’s outlook on the future of the research he started.